Targeted gene silencing in human embryonic stem cells using cell-penetrating peptide PepFect 14
There is an urgent need for a pharmacological agent that can specifically and safely correct the shared metabolic pathology, ideally by acting at both central (e.g., controlling appetite and cravings) and peripheral (e.g., improving insulin sensitivity, reducing hepatic fat and inflammation) levels to support and enhance existing behavioral strategies, thereby lowering the risk of advanced liver disease development across metabolic and alcoholic etiologies
Despite GSTP1 inhibition, the cause of insignificance in overall GST activity may be due to other GST isoforms remaining uninhibited, and compensatory mechanisms may upregulate other GST isoforms, indicating the need for further investigations
Farr OM, Sofopoulos M, Tsoukas MA, Dincer F, Thakkar B, Sahin-Efe A, et al
10.1016/S0891-5849(02)01006-7 80 KalanakyS.HafiziM.SafariS.MousavizadehK.KabiriM.FarsinejadA.et al (2016)